Novan preps to seek FDA approval for lead drug as competitor stumbles


A Durham-based pharmaceutical company plans to raise $15 million as it prepares to seek regulatory approval for its treatment for a viral skin infection.

Previous Meet Peoples, Pittsburgh's newest bank
Next M&A wrap: AffiniPay buys MyCase; Austin's busiest tech recruiter gets bigger